Skip to main content
NWBO
OTC Life Sciences

NW Bio Raises $5.5M in Streeterville Debt With 10% OID and 8% Interest

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.17
Mkt Cap
$289.958M
52W Low
$0.138
52W High
$0.339
52W Position info
23% above low
Off High info
50% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NWBO sits 23% above its 52-week low of $0.138.

Summary

Northwest Biotherapeutics signed a $5,505,000 loan with Streeterville Capital on October 26, 2026, carrying a 10% original issue discount and 8% interest, with no repayments for the first 8 months. The cash funds ongoing operations at a company that reported $595K of cash and a going concern warning in August.


Key Events · Financing and Capital Events · NWBO

  • New $5.5M Streeterville Loan

    On October 26, 2026 the company entered a Commercial Loan Agreement and Note with Streeterville Capital, LLC for $5,505,000, carrying a 22-month maturity.

  • Costly Terms: 10% OID, 8% Interest

    The loan carries an original issue discount of ten percent and interest at 8% per annum; prepayment at the company's election includes a 10% charge.

  • Repayment Starts June 2027

    No repayments are due for the first 8 months; beginning June 26, 2027 the loan amortizes in 14 equal monthly installments of principal at 110% of the pro rata amount plus accrued interest.

  • Cash Crunch Context

    The August 2026 10-Q reported $595K of cash, a $12.3M quarterly loss and a going concern warning; proceeds are earmarked for ongoing business operations.


Analysis · NWBO · Life Sciences

With $595K of cash and a going concern warning as of its August 10-Q, NW Bio needed near-term survival capital, not growth money, and this $5.5M loan fits that bill. The cost is steep: a 10% original issue discount plus 8% interest, and principal amortizes at 110% of the pro rata amount starting June 26, 2027, meaning the company repays more than it borrowed. No cash interest or principal burden arises for the first 8 months, which buys time, but the 14-month repayment schedule that follows will compete directly with trial spending. Prepayment is allowed at the company's election but carries a 10% charge, so an early refinancing is also expensive.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NWBO was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $290M. The 52-week trading range was $0.14 to $0.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NWBO - Latest Insights

NWBO
Nov 13, 2026, 4:36 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1565
Real-time Price: $0.1565 info
Change: $0 (0%) info
Market Cap: $266.932M info
NWBO
Oct 08, 2026, 5:15 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.148
Real-time Price: $0.1565 info
Change: +$0.0085 (+6%) info
Market Cap: $266.932M info
NWBO
Aug 14, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.192
Real-time Price: $0.1565 info
Change: -$0.0355 (-18%) info
Market Cap: $266.932M info
NWBO
Jul 31, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.164
Real-time Price: $0.1565 info
Change: -$0.0075 (-5%) info
Market Cap: $266.932M info
NWBO
Jul 31, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.164
Real-time Price: $0.1565 info
Change: -$0.0075 (-5%) info
Market Cap: $266.932M info